dc.description.abstract | Obective:To carry out an overview of the medical treatment of the benign prostatic hyperplasia using the combination drugs of alpha adrenergic uro-selective blockers(tamsulocin,alfuzocin) and the 5 alpha reductase iso-enzymes 1&2 inhibitor dutasteride . Data source :Review of researches don and those ongoing especially those sponsored and financed by GlaxoSmithcline in the multicenter international control trials. Data selction: Selected data from international researches on BPH from the following research groups MTOPS,PREDICT,PLESS,VCOOP,ALFIN,DUTASTERIDE 4-DATA 2004/PHASE 111a studies,COmbAT2007,SMART-1, also from GlaxoSmithkline data files.Data Extraction:Selection of research conclusions from various researches tested for clinical use by the international researchers.Data synthesis:From these the advantages of drug compliance on clinical use on BPH was analysed. | en |